Opko Health, Inc. Form 3
July 16, 2007

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement Opko Health, Inc. [OPK] UPPALURI SUBBARAO V (Month/Day/Year) 05/03/2007 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 4400 BISCAYNE (Check all applicable) **BOULEVARD, 15TH FLOOR** (Street) 6. Individual or Joint/Group 10% Owner Director _X__ Officer Other Filing(Check Applicable Line) (give title below) (specify below) _X_ Form filed by One Reporting Senior VP- CFO Person MIAMI, FLÂ 33137 Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security 2. Amount of Securities 4. Nature of Indirect Beneficial Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) Â Common Stock D 3,754,282 Common Stock 15,490,546 I See Footnote (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
--	--	--	--	--	--

Edgar Filing: Opko Health, Inc. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Warrants (Right to Buy)	(2)	03/27/2017	Common Stock	4,000,000	\$ 0.4984	I	See Footnote (3)
Warrants (Right to Buy)	(2)	01/11/2017	Common Stock	81,085	\$ 0.0002	I	See Footnote (4)
Warrants (Right to Buy)	(2)	01/11/2017	Common Stock	6,487	\$ 38.54	I	See Footnote (4)
Warrants (Right to Buy)	(2)	03/27/2017	Common Stock	22,124	\$ 0.672	I	See Footnote (4)
Warrants (Right to Buy)	(2)	03/27/2017	Common Stock	22,124	\$ 0.8473	I	See Footnote (4)
Warrants (Right to Buy)	(2)	03/27/2017	Common Stock	22,125	\$ 1.0467	I	See Footnote (4)
Warrants (Right to Buy)	(2)	03/27/2017	Common Stock	316,690	\$ 0.6728	D	Â
Warrants (Right to Buy)	(2)	03/27/2017	Common Stock	316,690	\$ 0.8473	D	Â
Warrants (Right to Buy)	(2)	03/27/2017	Common Stock	316,690	\$ 1.0466	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships					
1	Director	10% Owner	Officer	Other		
UPPALURI SUBBARAO V 4400 BISCAYNE BOULEVARD, 15TH FLOOR MIAMLÂ FLÂ 33137	Â	Â	Senior VP- CFO	Â		

Signatures

/s/Subbarao
Uppaluri

**Signature of Reporting Person

O7/16/2007

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- These securities are owned directly by The Frost Group, LLC. The reporting person disclaims beneficial ownership of these securities, (1) except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.
- (2) These warrants are immediately exercisable.

Reporting Owners 2

Edgar Filing: Opko Health, Inc. - Form 3

- (3) These warrants were acquired by The Frost Group as part of the consideration paid by the issuer for a line of credit extended by The Frost Group to the issuer in connection with the merger of Froptix Corporation into a wholly-owned subsidiary of the issuer.
- The Frost Group acquired these securities in connection with the merger of Acuity Pharmaceuticals, Inc. into a wholly-owned subsidiary (4) of the issuer in exchange for securities of Acuity held by The Frost Group immediately before the merger. On the effective date of the merger the closing sales price of the issuer's common stock was \$3.28 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.